Researchers at the University of Illinois at Chicago are comparing two common stimulant drugs with a placebo to evaluate their effect on sleep and behavior in children with attention deficit hyperactivity disorder.
For sufferers of Post Traumatic Stress Disorder (PTSD), sleep disturbances are among the most treatment-resistant symptoms and can lead to drug and alcohol abuse and even suicide.
The Food and Drug Administration (FDA) approved Altabax (retapamulin ointment) for topical treatment of impetigo, a skin infection caused by bacteria. Altabax is indicated for use in patients aged nine months or older.
Researchers from University of Berne in Switzerland revealed that dietary supplement chondroitin not helpful at easing the hip and knee pain of arthritis.
According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI?) ? a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS) ? also reduces vision loss in patients with relapsing MS.
Chondroitin, a dietary supplement used to treat osteoarthritis, is ineffective, a new meta-analysis — a study of published research — finds.
The drug pentoxifylline appears to have limited benefit in the first-line treatment of mouth ulcers due to recurrent apthous stomatitis, according to a report in the April issue of Archives of Dermatology, one of the JAMA/Archives journals.
Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.
A drug that slows disability and reduces relapse rates in multiple sclerosis (MS) has been found to also reduce vision loss in patients with relapsing MS. Vision loss is one of the most common and debilitating symptoms of MS.
Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec ?) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.